|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM372286348 |
| 003 |
DE-627 |
| 005 |
20240615233637.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240514s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.110234
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1441.xml
|
| 035 |
|
|
|a (DE-627)NLM372286348
|
| 035 |
|
|
|a (NLM)38740111
|
| 035 |
|
|
|a (PII)S1521-6616(24)00343-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ji, Yuan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Selective production of IL-33-neutralizing autoantibody ameliorates asthma responses and severity
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.06.2024
|
| 500 |
|
|
|a Date Revised 14.06.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2024 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a BACKGROUND: Natural anti-cytokine autoantibodies can regulate homeostasis of infectious and inflammatory diseases. The anti-cytokine autoantibody profile and relevance to the pathogenesis of asthma are unknown. We aim to identify key anti-cytokine autoantibodies in asthma patients, and reveal their immunological function and clinical significance
|
| 520 |
|
|
|a METHODS: A Luciferase Immunoprecipitation System was used to screen serum autoantibodies against 11 key cytokines in patients with allergic asthma and healthy donors. The antigen-specificity, immunomodulatory functions and clinical significance of anti-cytokine autoantibodies were determined by ELISA, qPCR, neutralization assays and statistical analysis, respectively. Potential conditions for autoantibody induction were revealed by in vitro immunization
|
| 520 |
|
|
|a RESULTS: Of 11 cytokines tested, only anti-IL-33 autoantibody was significantly increased in asthma, compare to healthy controls, and the proportion positive was higher in patients with mild-to-moderate than severe allergic asthma. In allergic asthma patients, the anti-IL-33 autoantibody level correlated negatively with serum concentration of pathogenic cytokines (e.g., IL-4, IL-13, IL-25 and IL-33), IgE, and blood eosinophil count, but positively with mid-expiratory flow FEF25-75%. The autoantibodies were predominantly IgG isotype, polyclonal and could neutralize IL-33-induced pathogenic responses in vitro and in vivo. The induction of the anti-IL-33 autoantibody in blood B-cells in vitro required peptide IL-33 antigen along with a stimulation cocktail of TLR9 agonist and cytokines IL-2, IL-4 or IL-21
|
| 520 |
|
|
|a CONCLUSIONS: Serum natural anti-IL-33 autoantibodies are selectively induced in some asthma patients. They ameliorate key asthma inflammatory responses, and may improve lung function of allergic asthma
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Anti-cytokine autoantibody
|
| 650 |
|
4 |
|a Asthma
|
| 650 |
|
4 |
|a IL-33
|
| 650 |
|
4 |
|a Prognosis
|
| 650 |
|
4 |
|a Severity
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-33
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Neutralizing
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a IL33 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin E
|2 NLM
|
| 650 |
|
7 |
|a 37341-29-0
|2 NLM
|
| 650 |
|
7 |
|a Toll-Like Receptor 9
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 700 |
1 |
|
|a Wang, Eryi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mohammed, Mohammed T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hameed, Najwa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Christodoulou, Maria-Ioanna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Xiaoyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Wei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fang, Zhangfu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jia, Nan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Haiqiong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Zhenwen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Shau-Ku
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a McSharry, Charles
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhong, Nan-Shan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xiao, Xiaojun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Jing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Damo
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 264(2024) vom: 20. Juni, Seite 110234
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:264
|g year:2024
|g day:20
|g month:06
|g pages:110234
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.110234
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 264
|j 2024
|b 20
|c 06
|h 110234
|